Q1 Earnings Estimate for SPRB Issued By Leerink Partnrs

Spruce Biosciences, Inc. (NASDAQ:SPRB) – Investment analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for Spruce Biosciences in a report issued on Tuesday, April 15th. Leerink Partnrs analyst J. Schwartz forecasts that the company will earn ($0.25) per share for the quarter. The consensus estimate for Spruce Biosciences’ current full-year earnings is ($1.00) per share. Leerink Partnrs also issued estimates for Spruce Biosciences’ Q2 2025 earnings at ($0.26) EPS, Q3 2025 earnings at ($0.26) EPS, Q4 2025 earnings at ($0.08) EPS, FY2025 earnings at ($0.67) EPS and FY2026 earnings at ($0.36) EPS.

Spruce Biosciences (NASDAQ:SPRB) last posted its quarterly earnings data on Tuesday, April 15th. The company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.37). Spruce Biosciences had a negative net margin of 555.23% and a negative return on equity of 62.10%. The company had revenue of $0.55 million during the quarter, compared to analyst estimates of $0.50 million.

Separately, Royal Bank of Canada cut their price target on Spruce Biosciences from $1.50 to $0.50 and set a “sector perform” rating on the stock in a research note on Wednesday. Six research analysts have rated the stock with a hold rating, According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $2.17.

Spruce Biosciences Stock Performance

SPRB stock opened at $0.12 on Friday. The stock has a market capitalization of $4.90 million, a PE ratio of -0.13 and a beta of 2.39. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.36 and a quick ratio of 5.36. The company has a 50 day moving average price of $0.33 and a 200 day moving average price of $0.41. Spruce Biosciences has a fifty-two week low of $0.11 and a fifty-two week high of $0.87.

Hedge Funds Weigh In On Spruce Biosciences

A hedge fund recently bought a new stake in Spruce Biosciences stock. Boothbay Fund Management LLC bought a new stake in Spruce Biosciences, Inc. (NASDAQ:SPRB) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 288,800 shares of the company’s stock, valued at approximately $121,000. Boothbay Fund Management LLC owned approximately 0.70% of Spruce Biosciences as of its most recent filing with the Securities and Exchange Commission (SEC). 91.71% of the stock is owned by institutional investors and hedge funds.

About Spruce Biosciences

Spruce Biosciences, Inc, a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial.